ART Advanced Research Technologies to Present at the BioContact Quebec Investor Conference
September 29 2008 - 2:26PM
Marketwired
ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a
Canadian medical device company and a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries,
announced today that Mr. Sebastien Gignac, ART's Chairman and Chief
Executive Officer, will present a company overview at the
BioContact investor conference being held at the Fairmount Chateau
Frontenac in Quebec City (Canada) from October 1 to 3. Mr. Gignac's
presentation will take place on Wednesday, October 1st, 2008, at 3
p.m. (EST) in the Place d'Armes Room.
BioContact is a leading biopharmaceutical partnership symposium,
gathering over 1000 participants from North America and Europe.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan� optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra�
line of molecular imaging contrast products provides image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART
is commercializing some of these products in a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in ART's most recent Annual Information
Form and the financial statements for the year ended December 31,
2007, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Chief
Financial Officer Jacques Bedard jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024